RxDoctor Payments Data

Michael Ross, DO

Family Medicine · Batavia, ILNPI 1366855454

Payments from drug & device makers

$3,015in general payments, 2019–2025

Across 29 payments — averaging $103.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$692
  • AstraZeneca$536
  • Exact Sciences$453
  • Lilly USA, LLC$368
  • Sanofi-aventis U.S. LLC$313
  • Axsome Therapeutics, Inc.$224
  • plus $429 from 4 others

What the payments were for

  • Food & beverage$3,015100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,015 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$169,083
Medicare patients
384
Services billed
6,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$163,676
JardianceEmpagliflozin88$121,016
EliquisApixaban82$90,631
RybelsusSemaglutide43$78,078
XareltoRivaroxaban87$68,263
MounjaroTirzepatide51$57,145
FarxigaDapagliflozin Propanediol26$42,731
TradjentaLinagliptin19$18,106
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$10,895
Breo ElliptaFluticasone/Vilanterol20$7,864
Atorvastatin Calcium740$7,615
Tamsulosin Hcl221$7,499
Repatha SureclickEvolocumab12$6,369
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$5,206
Metoprolol Succinate247$5,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$158$241,755147 claims
Boehringer IngelheimJardiance, Tradjenta$122$139,122107 claims
Lilly USA, LLCMounjaro$368$57,14551 claims
AstraZenecaFarxiga$536$42,73126 claims
GSKBreo Ellipta, Arnuity Ellipta$119$12,84537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Batavia

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →